Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Strategic Acquisition and Business Combination
WAT logo

Waters Corp Boosts Revenue 8% Amid $17.5B BD Biosciences Acquisition

WAT10-QFiling Date: 11/4/2025
Waters Corporation
Description

What this story covers

Waters Corp's Q3 2025 shows 8% sales growth to $799.9M, driven by pharma and recurring revenues. Key: $17.5B merger with BD Biosciences, expanding diagnostics. Solid liquidity supports $4B debt; merger risks include approvals and integration.

Story snapshot

CompanyWaters Corporation
TickerWAT
VariantStandard detailed
Duration13:17
Filing type10-Q
PeriodQ3 2025
IndustryTechnology
Accession0001193125-25-263533

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in